Visonneau S - Search Results

1

Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.

Cesano A, Visonneau S, Cioé L, Clark SC, Santoli D. Cesano A, et al. Among authors: visonneau s. Cancer Immunol Immunother. 1995 Mar;40(3):139-51. doi: 10.1007/BF01517345. Cancer Immunol Immunother. 1995. PMID: 7728772 Free PMC article.

2

A revertant TCR gamma delta + cell clone which has lost MHC nonrestricted cytotoxic activity but retains redirected killing upon stimulation of the CD3 receptor.

Visonneau S, Cesano A, Santoli D. Visonneau S, et al. Cell Immunol. 1995 Oct 15;165(2):252-65. doi: 10.1006/cimm.1995.1212. Cell Immunol. 1995. PMID: 7553890

3

Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.

Cesano A, Visonneau S, Santoli D. Cesano A, et al. Among authors: visonneau s. Cancer Res. 1995 Jan 1;55(1):96-101. Cancer Res. 1995. PMID: 7805048

4

Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.

Cesano A, Visonneau S, Cioé L, Clark SC, Rovera G, Santoli D. Cesano A, et al. Among authors: visonneau s. J Clin Invest. 1994 Sep;94(3):1076-84. doi: 10.1172/JCI117422. J Clin Invest. 1994. PMID: 8083348 Free PMC article.

5

Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.

Cesano A, Visonneau S, Clark SC, Santoli D. Cesano A, et al. Among authors: visonneau s. J Immunol. 1993 Sep 15;151(6):2943-57. J Immunol. 1993. PMID: 8104216

6

Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.

Cesano A, Pierson G, Visonneau S, Migliaccio AR, Santoli D. Cesano A, et al. Among authors: visonneau s. Blood. 1996 Jan 1;87(1):393-403. Blood. 1996. PMID: 8547668 Free article.

7

Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.

Cesano A, Visonneau S, Jeglum KA, Owen J, Wilkinson K, Carner K, Reese L, Santoli D. Cesano A, et al. Among authors: visonneau s. Cancer Res. 1996 Jul 1;56(13):3021-9. Cancer Res. 1996. PMID: 8674057 Clinical Trial.

8

Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.

Cesano A, Visonneau S, Pasquini S, Rovera G, Santoli D. Cesano A, et al. Among authors: visonneau s. Cancer Res. 1996 Oct 1;56(19):4444-52. Cancer Res. 1996. PMID: 8813139

9

Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.

Cesano A, Visonneau S, Wolfe JH, Jeglum KA, Fernandez J, Gillio A, O'Reilly RJ, Santoli D. Cesano A, et al. Among authors: visonneau s. Cancer Immunol Immunother. 1997 May;44(3):125-36. doi: 10.1007/s002620050365. Cancer Immunol Immunother. 1997. PMID: 9191872 Free PMC article.

10

Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.

Cesano A, Visonneau S, Rovera G, Santoli D. Cesano A, et al. Among authors: visonneau s. Anticancer Res. 1997 May-Jun;17(3C):1887-92. Anticancer Res. 1997. PMID: 9216640

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters